CRAMP (mouse) |
Catalog No.GA21286
One-Click Copy Product Info
|
CRAMP (mouse) is a cathelin-related antimicrobial peptide (AMP) expressed in embryonic and adult mice.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 376364-36-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
CRAMP (mouse) is a cathelin-related antimicrobial peptide (AMP) expressed in embryonic and adult mice[1]. AMPs exert multiple immunomodulatory effects that may be dominant under physiological conditions and lose their bactericidal properties in serum and tissue environments[2]. CRAMP (mouse) is an effective antibiotic against Gram-negative bacteria by inhibiting the growth of multiple bacterial strains and directly permeabilizing the inner membrane of Escherichia coli[3]. Mice lacking CRAMP are more susceptible to central nervous system pneumococcal infection, resulting in higher bacterial loads within the brain and outside the central nervous system, accompanied by reduced neutrophil infiltration and higher mortality[4]. CRAMP (mouse) is able to enhance the chemotactic response of bone marrow-derived stem/progenitor cells (BMSPCs) to a low α-chemokine stromal-derived factor 1 (SDF-1) gradient[5].
References:
[1] Gallo R L, Kim K J, Bernfield M, et al. Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse[J]. Journal of Biological Chemistry, 1997, 272(20): 13088-13093.
[2] Xia X, Cheng L, Zhang S, et al. The role of natural antimicrobial peptides during infection and chronic inflammation[J]. Antonie Van Leeuwenhoek, 2018, 111: 5-26.
[3] Mishra N M, Briers Y, Lamberigts C, et al. Evaluation of the antibacterial and antibiofilm activities of novel CRAMP–vancomycin conjugates with diverse linkers[J]. Organic & Biomolecular Chemistry, 2015, 13(27): 7477-7486.
[4] Kress E, Merres J, Albrecht L J, et al. CRAMP deficiency leads to a pro-inflammatory phenotype and impaired phagocytosis after exposure to bacterial meningitis pathogens[J]. Cell Communication and Signaling, 2017, 15: 1-15.
[5] Klyachkin Y M, Idris A, Rodell C B, et al. Cathelicidin related antimicrobial peptide (CRAMP) enhances bone marrow cell retention and attenuates cardiac dysfunction in a mouse model of myocardial infarction[J]. Stem cell reviews and reports, 2018, 14: 702-714.
| Cas No. | 376364-36-2 | SDF | |
| Formula | C178H302N50O46 | M.Wt | 3878.67 |
| Solubility | DMSO : 3.33 mg/mL (0.86 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 257.8 μL | 1.2891 mL | 2.5782 mL |
| 5 mM | 51.6 μL | 257.8 μL | 515.6 μL |
| 10 mM | 25.8 μL | 128.9 μL | 257.8 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)